The synNotch solution: UCSF scientists engineer a next-gen T-cell immunotherapy

CAR-T has been all the rage in cancer R&D for several years now, as a slate of biotech upstarts pursues highly promising work reengineering T cells into attack weapons by adding a chimeric antigen receptor that can zero in on particular cancer cells. The approach has been highly effective in acute lymphoblastic leukemia, triggering an attack on B cells by homing in on the CD19 antigen, a breakthrough that has inspired a race to the regulatory finish line with the first CAR-Ts. That approach, though, has run into some major obstacles when researchers move from the blood cancer to solid tumors. But now a group of scientists working with the University of California, San Francisco's Wendell Lim says it's come up with a new therapeutic model for T-cell engineering that promises to overcome that hurdle and make it a more precise weapon that can tackle solid tumors while avoiding off-target reactions that threaten patients. More from FierceBiotechResearch

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.